Article info

Download PDFPDF

Response to: ‘Comment on ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’’ by Pethoe-Schramm et al

Authors

  1. Correspondence to Professor Daniel Aletaha, Department of Rheumatology, Medical University of Vienna, 1090 Wien, Austria; daniel.aletaha{at}meduniwien.ac.at
View Full Text

Citation

Shafran IH, Alasti F, Smolen JS, et al
Response to: ‘Comment on ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’’ by Pethoe-Schramm et al

Publication history

  • Received July 10, 2020
  • Accepted July 13, 2020
  • First published July 31, 2020.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.